Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?

Author： Boren Todd P   Miller David S  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.6, Iss.6, 2010-11, pp. : 789-795

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted mutation analysis of endometrial clear cell carcinoma

By  

HISTOPATHOLOGY, Vol. 66, Iss. 5, 2015-04 ,pp. : 664-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high‐grade serous carcinoma

By  

APMIS (ELECTRONIC), Vol. 126, Iss. 1, 2018-01 ,pp. : 45-55

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diagnostic Impacts of Serum CA-125 Levels, Pap Smear Evaluation, and Endometrial Sampling in Women with Endometrial Clear Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 39, Iss. 5, 2016-04 ,pp. : 283-288

Karger

Access to resources Recommend Favorite

Hepatocyte nuclear factor‐1β is not a specific marker of clear cell carcinoma in serous effusions

By  

CANCER CYTOPATHOLOGY, Vol. 122, Iss. 2, 2014-02 ,pp. : 153-158

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: which patients with hepatitis B virus‐related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 908-910

John Wiley & Sons Inc

Access to resources Recommend Favorite